Finance

Lists
300601:SHE
Shenzhen Kangtai Biological Prods Co Ltd
CNÂ¥12.58
-2.25%
(-0.29) 1D
Sep 4, 3:04:37 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300601...
Open
CNÂ¥12.84
High
CNÂ¥12.97
Low
CNÂ¥12.56
Mkt. cap
14.46B
Avg. vol.
25.98M
Volume
16.27M
P/E ratio
167.53
52-wk high
CNÂ¥19.68
52-wk low
CNÂ¥10.70
EPS
CNÂ¥0.08
Shares outstanding
1.12B
No. of employees
2K
Open
CNÂ¥12.84
High
CNÂ¥12.97
Low
CNÂ¥12.56
Mkt. cap
14.46B
Avg. vol.
25.98M
Volume
16.27M
P/E ratio
167.53
52-wk high
CNÂ¥19.68
52-wk low
CNÂ¥10.70
EPS
CNÂ¥0.08
Shares outstanding
1.12B
No. of employees
2K
Profile
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products. Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
About Shenzhen Kangtai Biological Prods Co Ltd
CEO-
Employees1.96K
FoundedSep 8, 1992
Headquarters-
SectorBiotechnology
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
671.38M
609.64M
631.11M
641.89M
Cost of goods sold
110.97M
267.74M
182.40M
218.78M
Cost of revenue
110.97M
267.74M
182.40M
218.78M
Research and development expenses
123.15M
123.35M
84.28M
90.88M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
291.37M
283.35M
302.79M
284.34M
Operating expense
425.29M
428.59M
406.24M
402.08M
Total operating expenses
536.26M
696.33M
588.65M
620.87M
Operating income
135.12M
-86.69M
42.47M
21.03M
Other non operating income
-375.71K
308.38K
-2.04M
1.69M
EBT including unusual items
324.22K
45.26M
39.95M
1.37M
EBT excluding unusual items
125.91M
-104.26M
19.66M
-1.09M
Income tax expense
-11.26M
24.17M
6.35M
-12.75M
Effective tax rate
-3,472.08%
53.40%
15.89%
-932.00%
Other operating expenses
3.89M
14.05M
6.96M
12.14M
Net income
11.62M
21.17M
33.34M
17.05M
Net profit margin
1.73%
3.47%
5.28%
2.66%
Earnings per share
-
-
-
-
Interest and investment income
20.88M
13.75M
8.72M
9.41M
Interest expense
-30.13M
-30.16M
-29.50M
-29.76M
Net interest expenses
-9.24M
-16.42M
-20.77M
-20.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
212.79M
11.74M
140.90M
126.83M
Gain or loss from assets sale
-365.90K
934.47K
-
-5.69K
AI content may include mistakes. Learn more
Google apps